Skip to main content
. 2021 Mar 4;22(5):2576. doi: 10.3390/ijms22052576

Figure 2.

Figure 2

Effect of Empagliflozin (EMPA) on anthropomorphic measures in PCOS. Effect of EMPA on (A) BW, (B) cumulative food intake, (C) cumulative fluid intake, (D) body mass index (BMI), (E) total lean mass, (F) lean mass corrected by body weight (BW), (G) total fat mass, (H) fat mass corrected by BW, and (I) percent change in fat mass before and after three weeks of EMPA treatment. Data are expressed as mean ± SEM. Data were analyzed by two-way repeated measures ANOVA followed by Tukey post-hoc tests. Significant interaction was only observed for BW and percent change in fat mass. * p < 0.05 vs. untreated control rats; # p < 0.05 vs. untreated PCOS rats. n = 7–10 per group. CON: Control, CON+EMPA: Control+Empagliflozin, PCOS: Polycystic Ovary Syndrome, PCOS+EMPA: Polycystic Ovary Syndrome+Empagliflozin.